



FINANCIAL TEAR SHEET

CORPORATE PROFILE

Coherus is a late-stage biologics platform company focused on the global biosimilar market. Headquartered in the San Francisco Bay Area and composed of a team of industry veterans with decades of experience in pioneering biologics companies, our goal is to become a global leader in the biosimilar market by leveraging our team's collective expertise in key areas such as process science, analytical characterization, protein production and clinical-regulatory development. Our commercialization partnerships include global pharmaceutical companies in Europe, Asia and Latin America.

STOCK INFORMATION

CHRS (Common Stock)

Exchange	NASDAQ (US Dollar)
Price	\$12.05
Change (%)	▼ 0.5 (3.98%)
Volume	363,626
52 Week Low	\$8.05
Market Cap	\$724,858,411
Rolling EPS	-4.48
PE Ratio	N/A
Shares Outstanding	60,154,225

Data as of 04/19/18 4:00 p.m. ET



RECENT NEWS & UPCOMING EVENTS

- 04/19/18
[Coherus BioSciences Announces New Employment Inducement Grants](#)
- 04/02/18
[Coherus BioSciences Management to Present at the H.C. Wainwright Annual Global Life Sciences Conference in Monte Carlo, Monaco](#)
- 03/13/18
[Coherus BioSciences Announces New Employment Inducement Grants](#)

There are currently no events scheduled.

SEC FILINGS

Filing Date	Form
04/13/18	<u>DEFA14A</u>
04/13/18	<u>DEF 14A</u>
03/26/18	<u>8-K</u>
03/12/18	<u>8-K</u>

CORPORATE GOVERNANCE

<u>Denny Lanfear</u>	President, CEO and Chairman
<u>Barbara Finck, M.D.</u>	Chief Medical Officer
<u>Alan Herman, Ph.D.</u>	Chief Scientific Officer
<u>Jean-Frederic Viret, Ph.D.</u>	Chief Financial Officer
<u>Peter Watler, Ph.D.</u>	Chief Technical Officer
<u>Vince Anicetti</u>	SVP, Global Quality
<u>Lisa M. Bell, Ph.D.</u>	SVP, Regulatory Affairs
<u>Michael Fleming</u>	SVP, Commercial Strategy
<u>Matthew R. Hooper</u>	SVP, General Counsel

Data provided by Nasdaq. Minimum 15 minutes delayed.